Details:
FZ007-119 is a third-generation JAK inhibitor targeting TYK2 JH2. It's IND application is approved after preclinical studies for the treatment of plaque psoriasis, inflammatory bowel disease & rheumatoid arthritis
Lead Product(s): FZ007-119
Therapeutic Area: Dermatology Product Name: FZ007-119
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
OQL025 is a first-in disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors. It works by selectively targeting the key pathways that lead to EGFR inhibitor-induced rash.
Lead Product(s): OQL025
Therapeutic Area: Dermatology Product Name: OQL025
Highest Development Status: IND Enabling Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
AC-201 is a novel small molecule inhibitor of TYK2/JAK1 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-201 effectively binds to the pseudo kinase domain (JH2) of TYK2/JAK1.
Lead Product(s): Diacerein
Therapeutic Area: Dermatology Product Name: AC-201
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
OQL036 is a novel topical agent that locally alleviates the toxicities induced by capecitabine metabolites, and reduces the inflammation associated with capecitabine-induced hand-foot syndrome (HFS).
Lead Product(s): OQL036
Therapeutic Area: Dermatology Product Name: OQL036
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2023
Details:
LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple cytokine-induced signaling pathways in vitro and in vivo. LNK01004 is tissue-restricted inhibitor that can potentially prevent safety issues caused by systemic drug exposure.
Lead Product(s): LNK01004
Therapeutic Area: Dermatology Product Name: LNK01004
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
ICP-488 is a potent and selective TYK2 allosteric inhibitor that, by binding the JH2 domain, blocks the signal transduction of IL-23, IL-12, type 1 IFN and another inflammatory cytokine, thereby inhibiting the pathological process of autoimmune and inflammatory diseases.
Lead Product(s): ICP-488
Therapeutic Area: Dermatology Product Name: ICP-488
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy and safety profile.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Details:
The trial is a randomized, double-blind, vehicle-controlled, parallel-group, dose-escalationstudy in subjects to evaluate the safety, tolerability, and pharmacokinetics of GT20029 following topical single and multiple ascending dose administration.
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021
Details:
GT20029 is a topical androgen receptor degrader developed by using Kintor's in-house PROTAC platform. PROTAC is a small molecule composed of a recruiting element for a protein of interest; an E3 ubiquitin ligase recruiting element; and a linker bounding (i) and (ii).
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021